Practical management of inflammatory bowel disease patients during the COVID-19 pandemic : expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty
© 2020 Royal Australasian College of Physicians..
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Internal medicine journal - 50(2020), 7 vom: 11. Juli, Seite 798-804 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aysha, Al-Ani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 24.07.2020 Date Revised 18.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/imj.14889 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312336926 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312336926 | ||
| 003 | DE-627 | ||
| 005 | 20231225144212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imj.14889 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312336926 | ||
| 035 | |a (NLM)32656985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aysha, Al-Ani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Practical management of inflammatory bowel disease patients during the COVID-19 pandemic |b expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Royal Australasian College of Physicians. | ||
| 520 | |a The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Crohn disease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Rentsch, Clarissa |e verfasserin |4 aut | |
| 700 | 1 | |a Prentice, Ralley |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Doug |e verfasserin |4 aut | |
| 700 | 1 | |a Bryant, Robert V |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Costello, Samuel P |e verfasserin |4 aut | |
| 700 | 1 | |a Lewindon, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ghaly, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Connor, Susan J |e verfasserin |4 aut | |
| 700 | 1 | |a Begun, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine journal |d 2001 |g 50(2020), 7 vom: 11. Juli, Seite 798-804 |w (DE-627)NLM113582811 |x 1445-5994 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:7 |g day:11 |g month:07 |g pages:798-804 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imj.14889 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 7 |b 11 |c 07 |h 798-804 | ||